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ABSTRACT 
 
We have reacted [Pt(Me4en)(D2O)2]
2+
 [Me4En=N,N,N’N’-
tetramethylethylenediamine] with Selenomethionine (SeMet), Methionine (Met), and 
Methylselenocysteine (MeSeCys).  When MeSeCys was reacted with 
[Pt(Me4en)(D2O)2]
2+
, we observed both stereoisomers of Se,N chelates, as well as 
[Pt(Me4en)(MeSeCys)Cl]
+
 from 
1
H NMR Spectroscopy; the latter formed due to the 
presence of Cl
-
 in the solution.  Both isomers of the chelate seemed to form 
proportionally to one another, not favoring a specific stereoisomer.  Eventually the 
[Pt(Me4en)(MeSeCys)Cl]
+
 products became Se,N chelates.  We incubated SeMet with 
NaCl for 30 minutes and then mixed with [Pt(Me4en)(D2O)2]
2+
; we saw equal amounts of 
the [Pt(Me4en)(SeMet)Cl]
+
 isomers along with a specific stereoisomer of the Se,N chelate 
forming first (R chirality), then approximately two hours later the (S) chirality formed.  
Previously, Met and [Pt(Me4En(D2O)2]
2+
 have been studied by prior students and there 
were no chiralities favored in the reaction.  There were S,N chelates formed, but no 
specific isomer favored over another.  We obtained equal amounts of SeMet, Met and 
[Pt(Me4en)(D2O)2]
2+
 and mixed the solutions together to see which amino acid would 
platinate first, either SeMet or Met.  The NMR spectra we observed showed that SeMet 
attached first to [Pt(Me4en)(D2O)2]
2+
, with the (R) chelate forming first, then the (S) 
 iii 
 
chelate.  Met was slow to react, and we saw both chelates form at approximately equal 
rates. 
 
 
 
 
 
 
 
 
 
 
 
 
Keywords: Cisplatin, Selenomethionine, Selenocysteine, Bulky Platinum (ll) Compounds 
 iv 
 
 
 
 
 
 
 
 
Dedicated to my friends, family and my professors. 
 
 
 
 
 
 
 
 
 
 
 
 v 
 
 
ACKNOWLEDGEMENTS 
 
 
 This project would not have been possible without the help and support of many 
people.  I am very thankful for my advisor and professor, Dr. Kevin Williams, for taking 
the time and helping me with everything from my homework to some of life’s personal 
decisions!  I would also like to thank several other professors for the help and 
encouragement, to keep on chugging through this journey, and the many laughs; Dr. 
Pesterfield, Dr. Rajalingham, and Dr. Nee.  I would also like to thank many people of the 
Honors College for the help in being one of the first successful Honors in the Major 
graduate; Dr. Audra Jennings, Dr. Ami Carter, and Dr. Cobane.  I would also like to 
thank the Western Kentucky University Chemistry Department for the financial support 
to go to the many research conferences; Dr. Webb, and Shannon Marble. 
 Last but not least, I would like to thank my family and friends.  Their support, 
love, encouragement and even financial support, gave me the confidence that I needed to 
keep on going, has shown me I can do anything, I just may need some encouragement!   
 
 
 
 
 
 vi 
 
 
VITA 
 
 
September 17, 1985………………………………………Born-Louisville, Kentucky 
2010………………………………………………………WKUREU Research Fellowship 
2010……………………………………………………….Jefferson Community College      
2003……………………………………………………….Bullitt East High School 
 
PUBLICATION 
K. Williams, R. Dudgeon, S. Chmley, S. Robey; Inorganica Chimica Acta; 368 (2011) 
187-193 
 
 
 
FIELDS OF STUDY 
 
1
st
 Major: Biochemistry 
2
nd
 Major: Chemistry 
 
 
 
 
 vii 
 
 
TABLE OF CONTENTS 
 
 
Page 
Abstract…………………………………………………………………………………..ii 
Dedication………………………………………………………………………………..iv 
Acknowledgements……………………………………………………………................v 
Vita………………………………………………………………………………………vi 
List of Figures…………………………………………………………………...............viii 
Chapters: 
1. Introduction………………………………………………………………………..1 
2. Materials and Methods……………………………………………………………7 
3. Results………………………………………………………………………….....9 
4. Discussion………………………………………………………………………..17 
Bibliography……………………………………………………………………………..22 
 
 
 
 
 
 
 
 
 
 
 
 viii 
 
LIST OF FIGURES 
 
 
 
Figure                                                                                                            Page 
1. Cisplatin…………………………………………………………………………..1 
2. Structures (amino acids)..………………………………………………………...4 
3. Structures (platinum complexes)………………………………………………....6 
4. Pt(Me4en) and MeSeCys NMR……………………………………………….....10 
5. Pt(Me4en) and MeSeCys NMR………………………………………………10-11 
6. Pt(Me4en) and MeSeCys NMR……………………………………………….…11 
7. Pt(Me4en) and SeMet NMR………………………………………………….….13 
8. Pt(en) and MeSeCys NMR………………………………………………….…...16 
9. Pt(en) and MeSeCys NMR……………………………………………………....16 
                                                                                                                                 
 
 
 
 
 1 
 
CHAPTER 1  
INTRODUCTION 
Cancer affects all races, ethnicities, genders and all locations of the world.  There are 
many types of cancers, some are more predominant in particular genders or races than 
any others, some are slow growing while some spread very rapidly.  According to the 
National Cancer Institute of the Surveillance Epidemiology and End Results Statistics 
Fact Sheet it is estimated that 11,957,599 men and women in the United States have had a 
history of cancer by January 1, 2008.
1
  There are a few different options to try to treat and 
cure the cancer, but there is still ongoing research to come up with more effective yet less 
toxic treatments.  One popular area of anticancer medication research involves the use of 
platinum (II) compounds.  Currently there are a few platinum anticancer medications 
FDA approved for the treatment of cancers; cisplatin, carboplatin, and oxaliplatin.  
Unfortunately, like many medications, side effects, resistance and toxicity become a 
problem with these medications. 
Figure 1: 
 Pt
ClCl
H3N NH3
Figure 1 contains the structure of Cisplatin  
(cis-diamminedichloroplatinum (II)). 
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Cisplatin (cis-diamminedichloroplatinum (II)) was the first platinum anticancer 
medication approved for the treatment of cancer by the FDA in 1978.
2
  The anticancer 
activity was discovered by accident in the 1960’s by Barnett Rosenberg when he was 
trying to monitor cell growth and division of the bacteria E. coli.
2
  The cell division was 
inhibited while the cell growth was not bothered.
2
  This was later tested in sarcomas in 
rats and it was found that the platinum (II) complex was very effective in reducing the 
mass of the tumors.
2
  This finding led to other conformational testing in various tumor 
cell lines and eventually led to the FDA approval of the medication for testicular and 
ovarian cancers.
2
 
The anticancer activity comes from the platinum drug binding to DNA at the N7 
position of the guanine residue on the double helix, forming a crosslink.  The formed 
crosslink forces the double helix to bend in a distorted manner, which leads to apoptosis.  
In addition to monoadducts, there are three different types of possible crosslinks that can 
be formed giving rise to the anticancer activity: intrastrand crosslink, interstrand crosslink 
and a DNA-protein crosslink.
3
  Typically a monoadduct is initially formed, but then the 
complex goes on to form one of the other three crosslinks.
3
  High mobility group proteins 
are also thought contribute to the anticancer activity.
3
  These proteins bind to the 
platinum-DNA crosslink not allowing the cell to participate in repair mechanisms.
3
   
A theory in chemistry called the Hard Soft Acid Base Theory; also known as the 
donor-acceptor theory, helps explain why the platinum (II) complexes react with 
particular amino acids and molecules.  The theory was developed in the 1960’s by Ralph 
Pearson.
4
  The idea helps explain many reactions in chemistry; a base is defined as an 
electron-donor and an acid is defined as an electron-acceptor.
4
  A covalent bond joins the 
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two together and forms an adduct, complex or a coordination complex.
4
  When a 
particular acid can accommodate one base (ligand) it is often referred to as a monodentate 
ligand.  Where as if there is more than one donatable nonbonding electron pairs it is often 
referred to as either polydentate, bi-, tri-, tetra-, hexa- dentate, or chelating ligand.
4
  The 
HSAB Theory helps in forming an idea as to what adduct will form after a reaction 
because of classifying atoms as either hard/soft acids or bases.  Typically hard acids are 
atoms that have a relatively high charge ( ≥3+ ), small size and low electronegativity (.7-
1.6).
4
  Particularly atoms located in the s and f blocks, and higher charged ions on the left 
of the d block have low electronegativity.
4
  Hard bases usually have a high 
electronegativity and are small in size.  There are only 2 atoms within the 
electronegativity range of 3.4-4, oxygen and fluorine.
4
 So, hard bases are typically ones 
with either oxygen or fluorine as the donor atom.  Soft acids are typically classified as 
large size (1
+
, 2
+
), low charge and intermediate to high electronegativity (1.9-2.5).
4
  
Specific examples include Hg
2+
, Cu
+
, and Ag
+
.
4
  Soft bases include those that have 
intermediate to high electronegativity (2.1-3.0) and are large in size leading to 
polarizability.
4
  Particular examples of soft bases include S
2-
, Se
-
, I
-
, and Br
-
.
4
   
Platinum is considered a “soft acid” under the Hard/Soft Acid/Base Theory, 
which means the platinum is more likely to react with “soft bases.”  The atoms become 
“softer” going down the columns, thus, sulfur is softer than oxygen and selenium is softer 
then sulfur.  These particular atoms are important because two amino acids contain a 
sulfur atom, methionine and cysteine, as well as a nitrogen and oxygen atom.   Selenium 
is of importance because two other amino acids contain a selenium atom, 
selenomethionine and selenocysteine.  Selenomethionine is produced unintentionally in 
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the body while selenocysteine is made deliberately; however, it is still unknown the 
purpose and function of selenomethionine.  Selenocysteine, however, is currently being 
called the 21
st
 amino acid, and is known for its antioxidant properties.  Since selenium is 
softer then sulfur, it would be predicted that the selenium containing amino acids would 
be kinetically favored in a platinum (II) complex rather than the sulfur containing amino 
acids.   There are proteins in the body that contain either one or more of these selenium 
containing amino acids, which would also be thought that the platinum compound could 
react with these proteins before it even reaches the DNA
5.
  Typically it is thought that the 
major mechanism of cell death is the binding of the platinum complex to DNA, it is also 
possible that part of the mechanism could be contributed by the protein reacting with the 
platinum compound as well
5
.   
Figure 2: 
 
 
 
 
Once cisplatin enters the blood stream it remains with its initial ligands as shown 
in figure 1.  The Cl
-
 concentration is so high in the blood stream that the chlorides remain 
attached to the platinum, leaving the compound at a neutral charge.
5
  Since it’s now 
neutrally charged, the complex can enter the cytosol of the cell via the cell membrane.  
Once this occurs, the chloride ligands are displaced by water molecules, now leaving the 
NH
3
+ O
O
Se
NH
3
+
O
S
O
Figure 2 shows the selenomethionine 
and methionine molecules. 
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complex positively charged giving it the option to react with the DNA or proteins.
5
  If 
cisplatin reacts with DNA it either leads to cell repair or cell death, while if it reacts with 
proteins  this can trigger toxicity and/or resistance.
5
 
As with any drug in the medical field there are many side effects with the use of 
cisplatin, including but not limited to, nephrotoxicity, hematological toxicity, ototoxicity, 
neuropathy and seizures. Also, as with many chemotherapy agents, all cells in the body 
are affected by the antitumor drug.  Cisplatin affects the cancerous cell as well as other 
normal, healthy cells in the body.  With all of these many and harsh side effects on the 
body, researchers are trying to develop a better, less toxic anticancer medication.  It is 
thought that toxicity is created by competitive protein binding and could possibly be 
controlled with a rescue agent being given in conjunction with the platinum therapy.
6
  A 
rescue agent is considered to be a sulfur-containing ligand, that can improve side effects 
without affecting the antitumor activity, by either preventing or reversing the Pt-S bond 
in proteins.
6
  But first, one must understand how the side effects are caused in the body, 
what biomolecules are being affected.  With basic coordination chemistry S-donor 
ligands in proteins will rapidly produce the most stable bonds with Pt complexes.  It can 
also react with the lone pairs of N atom in amino acid side chains.  There are a few amino 
acids that contain an S-donor ligand, including cysteine and methionine, that are located 
in particular proteins.    
As stated earlier, selenium is “softer” than sulfur according to the hard-soft acid-
base (HSAB) theory.  Since it’s already known that Pt has a high affinity for sulfur 
atoms
6
, it could potentially also have a high affinity for selenium-containing amino acids, 
selenomethionine and selenocysteine.  When Pt binds to DNA, it typically always reacts 
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with 2 adjacent guanines (specifically the N(7) atom because its more nucloephilic) more 
predominantly than with anything else.  Because of the square planar geometry of 
cisplatin, when it bonds to guanine, the Pt-G bond rotates fast and spins freely.  To slow 
the rotation of the bond, bulk was added to the cisplatin molecule creating a new 
platinum complex [Pt(Me4en)(D2O)2]
2+
  (Me4en=tetramethylethylene diamine).  When 
the [Pt(Me4en)(D2O)2]
2+ 
is reacted with guanine, it slows down the rotation spin so that 
one can characterize the products.
3
  Adding the bulk to the platinum compound has 
delivered many results when reacted with guanine, as well as amino acids.  For example, 
when [Pt(Me4en)(D2O)2]
2+
  is reacted with excess methionines, a bis-product is formed.
5
  
When reacting selenomethionine with the same platinum complex, the results are not the 
same.  So, with this it is important to study how these platinum compounds with bulky 
ligands react with these amino acids.  Using bulky platinum compounds with amino acids 
has given insight to the kinetics and thermodynamics of the reaction. 
Figure 3 
a) b) 
 
 
 
 
 
 
N N
Pt
OD2OD2
Figure 3 shows the structure of a)  [Pt(Me4en)(D2O)2]
2+  
N,N,N’,N’,-tetramethylethylenediamine platinum (ll) diaqua, 
and b) [Pt(en)(D2O)2]
2+ ethylenediamine platinum (ll) diaqua 
Pt
N N
OD2 OD2
H2H2
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CHAPTER 2 
 
 
MATERIALS AND METHODS 
 
 
Synthesis of Pt compounds: All platinum compounds used were synthesized by 
other students in the Dr. Williams’ lab based on methods of Williams et al.6  For 
[Pt(Me4en)(D2O)2]
2+
, all solutions were made as a 10 mM solution, using 4.4 mg of the 
platinum compound and 1 mL of deuterium oxide.  [Pt(en)(D2O)2] solutions were made 
using 4.1 mg of the platinum compound in 1mL of deuterium oxide. 
Preparation of solutions: All amino acid containing compounds in solutions 
were all made to be around 5 to 10 mM, and around a pH of 4 to 5.  For the reaction 
involving SeMeCys and Pt(Me4en), the platinum compound was made as a       10 mM 
solution using 4.4 mg of platinum compound in 1 mL of deuterium oxide.  SeMeCys was 
made as 1.4 mg of amino acid in 1 microliter of deuterium oxide giving a 10 mM 
solution.  The final solution was made to be 300 microliters of each mixed together to 
give a final concentration of 5 mM. 
For the reaction involving selenomethionine, sodium chloride and 
[Pt(Me4en)(D2O)2]
2+
, 0.3 mg of sodium chloride was mixed with the platinum compound 
and allowed to mix for 30 minutes.  Selenomethionine was made using 4.1 mg of 
selenomethionine in 1 mL of deuterium oxide.  Then using theselenomethionine at pH 4, 
it is mixed with the sodium chloride and platinum solution; 300 microliters were used of 
each solution to mix.  Also, we wanted to mix the same reactants together, but add the 
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sodium chloride to the solution at a different time.  For this reaction, 500 microliters of 
the selenomethionine solution and added 0.3mg of sodium chloride and allowed to mix 
for 30 minutes and achieve a final pH of 7.66.  Then, adding 300 microliters of this 
SeMet-NaCl solution, to 300 microliters of the [Pt(Me4en)(D2O)2]
2+ 
 solution.   
The solutions of SeCys with Pt(en) were made at different ratios, for the 2:1 ratio 
solutions they were made via the following reaction.  1 mg of SeCys was first mixed in 
1mL of deuterium oxide and then the pH was raised to 7, then 2.5 mg of the platinum 
compound was added.  The pH was then checked and raised back to a pH of around 7.  
The second 2:1 solution the pH was not raised back up to 7 after adding the platinum 
compound, it was left around a pH of 3.  For the 1:1 solutions, 1 mg of SeCys was mixed 
with 1 mL of deuterium oxide and then the pH of was raised to 7 to allow for solubility.  
Then 1.2mg of platinum compound was raised to the SeCys solution made and the pH 
was then raised back up to 7.  The pH of the second 1:1 solution was not adjusted back to 
7, it was left at around a pH of 3.   
The solutions containing SeMeCys and Pt(en) were also made at different pH’s.  
The first solution was made by 1.1 mg SeMeCys in 1 mL of deuterium oxide and then 2.5 
mg of Pt(en) were added and left at pH 3.  The second solution was made using same 
amount SeMeCys and same amount of the platinum compound except the pH was then 
raised back up to 7.   
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CHAPTER 3 
 
RESULTS 
 
 
Reaction of MeSeCys and [Pt(Me4en)(D2O)2] 
2+ 
.  The addition of                         
methyl-selenocysteine (MeSeCys) to [Pt(Me4en)(D2O)2]
2+
 led to a mono adduct at the Se 
atom; figure 5 shows the mono adduct.  The MeSeCys used in the experiment contains 
the chloride ion in the commercial sample.  When Se binds to Pt this is what leads to the 
two different isomers seen in the NMR spectrum.  Initially, both isomers of the mono 
adduct are seen, Pt(Me4en)(MeSeCys-Se),(D2O) 
2+
. With the chloride in the mixture the 
mono adduct formed as well, [Pt(Me4en)(Cl)(MeSeCys)] 
+
, with a characteristic singlet at 
2.45 ppm and 2.31 ppm using 
1
H NMR.
 
 Eventually, the chloride ions dissociate from the 
complex allowing both isomers of the Se,N chelate to form, Pt(Me4en)(MeSeCys-Se,N)
+
, 
at 2.56 ppm and 2.49 ppm.  Over time the chloride adducts were forming proportionally 
to the MeSeCys chelates, and that both isomers of the Se,N chelate were forming 
relatively proportional to one another.  With both 1H NMR signals from the Se,N chelate 
forming at about the same rate, this is associated with no particular stereoisomer being 
preferred during the reaction.   Eventually, both of the chloride mono adduct signals 
slowly diminish giving rise to more Se,N chelates forming and allowing free chloride to 
form. 
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Figure 4:  
 
 
 
 
 
 
 
Figure 5: 
 
 
 
 
 
 
 
 
 
MeSeCys chelates  
2.0 ppm 3.0 ppm 
Figure 4 shows the 1H NMR 
spectrum for our reaction 
MeSeCys and Pt(Me4en) the 
initial reaction.  Here the 
MeSeCys chelates are noted. 
2.40 2.49 2.58 
2.58 2.49 2.40 
MeSeCys Chelates 
Chloride adducts 
In this NMR spectra both chelates are 
forming at around equal rates, while the 
chloride adduct signal still growing. 
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Figure 6: 
 
 
 
 
 
 
Reaction of [Pt(Me4en)(D2O)2 ] 
2+
, SeMet and NaCl.  When the last experiment with 
MeSeCys allowed both isomers of the Se,N chelate to be seen, it was decided to add NaCl 
to Pt(Me4en)(D2O)2
2+
.  After approximately 30 minutes, the chloride mono adduct is 
2.40 2.49 2.58 
Figure 5: Overall in these spectrum from the kinetics run, the MeSeCys chelates 
that have formed, no isomer is preferred when forming.  Also seen here the 
chloride adducts form, but eventually convert to all MeSeCys chelates. 
2.6 2.40 
MeSeCys chelates 
Figure 6:  Here, approximately 24 hours later, the chloride adducts 
have converted to all MeSeCys chelates in solution. 
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forming, [Pt(Me4en)(Cl)(D2O)]
+
, associated with 
1
H NMR singlets at 2.84 ppm and 2.85 
ppm.
6
  When adding the [Pt(Me4en)(Cl)(D2O)]
+
  to SeMet, two peaks are seen at 2.38 and 
2.39 ppm that grew at approximately equal rates and formed [Pt(Me4en)(SeMet-Se)Cl]
+
.
6
  
After approximately 5 days the chloride ligand dissociate from the complex and allow the 
Se,N chelate to form singlets at approximately 2.58 ppm and 2.48 ppm by 
1
H NMR 
[Pt(Me4en)(SeMet-Se,N)]
+
.
6
  
 The same experiment was completed with equal molar concentrations but 
changed what the incubated NaCl was mixed with.  First, NaCl was reacted with SeMet 
for 30 minutes and then added [Pt(Me4en)(D2O)2]
2+
.  Immediately the form mono-
chloride adducts with singlets at 2.38 and 2.39 ppm, [Pt(Me4en)(SeMet-Se)Cl]
+
, and the 
same Se,N chelates at 2.58 and 2.48 ppm.  With both isomers of the chelate, 
[Pt(Me4en)(SeMet-Se,N)]
+
 forming singlets at 2.58 and 2.48 ppm on the 
1
H NMR 
spectrum.  First, the R isomer shows up immediately and a little of the S isomer is a little 
slower reacting.  After approximately two hours both isomers have formed equal 
amounts.  Here it’s discovered that since there are the two isomers showing with a 
preference for one over the other, obviously one is easier to form than the other.  With the 
methyl group of the SeMet giving direction towards the bulky Me4en ligand in the (S) 
position, it is less likely to form due to the bulkiness of the ligand and because of the 
sterics that are created when the Se,N chelate forms.  However, when the methyl group is 
directed outward from the Me4en ligand, the chelate is easier to form, thus giving a larger 
singlet signal on the NMR spectrum. 
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Figure 7: 
 
 
 
 
 
 
 
 
 
Reaction of [Pt(en)(NO3)2 ]
2+
 and SeCys:  In the following reactions, SeCys was added 
to D2O and then the pH was raised to 7 to allow SeCys to fully dissolve in solution
7
.  
After pH was adjusted and SeCys was in solution, [Pt(en)(NO3)2 ]
2+
 was added.  When 
the platinum complex was added to the SeCys the pH would immediately drop to 
approximately 3.  Then either the solution was left at pH 3 or brought back up to around 
pH 7.  There were four different solutions made, two pH 7 solutions and two pH 3 
solutions, all with different amounts of [Pt(en)(NO3)2]
2+
. 
2.50 2.40 
SeMet Chelate (R) Isomer  
SeMet Chelate (S) Isomer 
Chloride Adducts 
2.40 2.50 
SeMet Chelate (S) Isomer 
SeMet Chelate (R) Isomer 
Chloride Adducts 
Figure 7:  Here we see at the begininning of the 
reaction the R isomer is already predominiately formed, 
while the S isomer has barely even formed at all.  We 
can also see here the chloride adducts have also formed 
again, showing both isomers of the monoadducts that 
formed. 
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 The first solution made was a 2:1 ratio, meaning there were two platinum 
complexes for every one selenocysteine complex in solution, and the pH was brought 
back up to 7.   This would allow for one platinum atom for every one selenium atom in 
solution.  The second solution made was also brought back up to pH 7, but this was made 
as a 1:1 ratio, meaning there was one platinum complex for every one selenocystine 
complex.  This gives one platinum atom per two selenium atoms in solution.  The initial 
color of both solutions was yellow, approximately four days later the solution had turned 
colorless with black precipitate in it.  The pH of the 2:1 solution dropped to 4.40 after 
four days, while the 1:1 solution dropped to pH 5.30 after four days.  The 
1
H NMR 
spectrum showed that the en ligand stayed on both platinum compounds during the 
reaction because there were no peaks at or around 3.33 ppm, which is typically where the 
singlet for the en ligand would be. 
 Both of the pH 3 solutions were made the same way, one was a 2:1 ratio at pH 3 
and the other was a 1:1 ratio at pH 3.  Initially the solutions were colorless with no 
precipitate, while four days later both solutions had turned yellow with black precipitate 
in it.   The color changes led to checking the pH of both solutions and in fact the pH had 
dropped.  For the solution that was a 2:1 ratio the solution dropped to 1.90, while the 1:1 
ratio solution was 2.90.  Taking a look at both solutions after another four more days and 
the solution had turned a darker yellow-brown color with the black precipitate still in it.   
The pH of both solutions was checked again, while the 2:1 ratio solution had remained 
the same, the 1:1 ratio had actually increased to 3.50.  After running both solutions in the 
NMR, it was noted that the en ligand had come off of the platinum compound by the 
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singlet at 3.33
8
.  Typically the ligand dissociation requires two Se ligands to be 
coordinated to the complex. 
 Both solutions that were initially at pH 7 were dropped to pH 3 to see if the en 
ligand would dissociate from the platinum complex.  Both ratios of the platinum complex 
were left the same, but adjusted the pH back to 3, and both solutions remained colorless 
even after the pH adjustment was made.  Initially with the NMR spectrum there were no 
new peaks noted, however, a few peaks on the spectrum continuously decreased in size 
when it reached 48 hours after making the pH adjustment.  There is a singlet at 2.33 ppm 
that occurs at pH 7 with both ratios of solutions; however, after dropping the pH back 
down to 3, the singlet eventually completely diminishes.  Continuously monitoring this 
reaction for about a week, the en ligand never comes off of the platinum complex. 
Reaction of SeMeCys and [Pt(en)(NO3)2]
2+
: The last experiment gave the idea to try 
SeMeCys and the same platinum complex used above in the next reactions.  For one 
solution the pH was left at 3 after mixing in the platinum complex, and then raised the pH 
of the other solution back to 7 after mixing in the platinum complex.   
 The first solution was made at a pH of 3, and an overnight kinetic reaction was 
ran for 12 hours on the 
1
H NMR.  Based upon the singlet at 3.33 ppm, this shows that the 
en ligand comes off of the main platinum compound.  The peak is seen pretty quickly in 
the reaction, actually almost immediately.  
 The second solution was made and then raised back up to a pH of 7 and a proton 
kinetics run was completed.  With the solution being at a higher pH than the previous 
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solution, the en ligand never comes off.  Comparing data from the initial run and a few 
weeks later, the 3.33 ppm peak never shows up.   
 With both solutions, a significant amount of unreacted SeMeCys and Pt(en) was 
seen during the course of both reactions.  These reactions also help reiterate that the en 
ligand comes off at a low pH, and doesn’t at a higher pH.   
Figure 8:   
 
 
 
 
Figure 8:  This is the initial mixing of 
the pH 3 sample of MeSeCys and 
Pt(en) for the NMR 
2.33 ppm 3.5 ppm 
Figure 9:  This is the same reaction at 
the same pH only 15 hours later.  The 
unreacted platinum complex and 
MeSeCys is still seen here. 
Figure 9: 
2.33 ppm 3.5 ppm 
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CHAPTER 4 
 
 
 DISCUSSION 
 Part of the purpose of these experiments was to see the effects that bulky platinum 
(II) compounds have when reacted with selenium-containing amino acids, in particular 
selenomethionine and selenocysteine.  Due to being unable to actually purchase 
selenocysteine, methylselenocysteine (MeSeCys) and selenocystine (SeCys) were 
purchased.  Initially it was wanted to start working with selenocysteine and reacting it 
with the platinum compounds, methylselenocysteine was used first.  After this reaction 
was completed, the obtained results showed that two isomers were being formed, which 
was caused from there being a chloride ion in solution from the methylselenocysteine.  
This gave the idea to try sodium chloride with selenomethionine and the platinum 
compound to see if any steric effects or isomers were forming.  Back to the 
selenocysteine idea, it was ended up that using selenocystine for the next reactions with 
the Pt(en) compound.  After not getting very good results, next the methylselenocysteine 
with the Pt(en) compound was repeated; this also did not help come to any conclusion for 
the seleocysteine project.   
 When the MeSeCys reacted with the Pt(Me4en) compound, the chloride adduct 
and MeSeCys chelate signals had formed in the NMR spectrum.  Over time the chloride 
adducts begin to form relatively proportional to the MeSeCys chelates being formed.  
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Eventually the chloride adducts dissociate from the platinum compound, which was 
shown by the NMR spectra, leaving with only two peaks for both isomers of the chelates 
being formed.  This information explains that the chloride ions from the MeSeCys are 
removed from the amino acid to form a monoadduct with the Pt(Me4en) complex.  Also, 
both isomers of the MeSeCys chelates form at relatively proportional rates.  When this 
showed that both isomers for the chelates were being formed, it was decided to try a 
similar reaction with selenomethionine and the same platinum compound. 
 For the similar reaction sodium chloride was incorporated two different ways into 
the solution.  The Pt(Me4en) complex was mixed with sodium chloride and after 
approximately 30 minutes there were peaks that were associated with the formation of 
[Pt(Me4en)(D2O)Cl]
+
.  There were two singlets formed at 2.84 ppm and 2.85 ppm that 
were essentially assigned to the two methyl groups of the Me4en ligand.  Then the 
selenomethionine was added to the solution, this gave peaks at 2.38 and 2.39 ppm, that 
corresponds to the Se-CH3 groups formed by the product [Pt(Me4en)(SeMet-Se)Cl]
+
.  
After approximately 5 days, these monoadducts form to Se-N chelates giving 
[Pt(Me4en)(SeMet-Se,N)
+
.  It also noted that with the isomers that were formed, one was 
forming at a relatively fast rate compared to the other.  The R isomer was formed first and 
slowly the S isomer was formed.  The methyl group from the SeMet is sterically hindered 
from the methyl groups of the platinum complex.  When the S isomer is formed, there is 
less room for the methyl group to exist, thus it wouldn’t be expected to see this isomer 
form particularly fast.  When the R isomer is formed, there isn’t anything sterically 
hindering the methyl group, thus it is easier and faster in forming the chelate.   Also, the  
SeMet was mixed with sodium chloride and allowed to mix for 30 minutes, then adding 
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the platinum compound.  With this experiment, the same results are seen as did with the 
previous way the solution was mixed.  The R isomer forms first and then slowly the S 
isomer forms.  However, with this mixture the monoadduct is not seen like that its 
formed in the previous experiment.  Finally, it was finally obtained, a great NMR 
spectrum for the isomers involved in the chelate formation, eventually it was decided to 
try the SeCys with a different platinum compound.   
 Using selenocystine with the Pt(en) complex gave very interesting results, 
however, it has not been able to classify peaks and determine what type of products that 
are obtained.  With these experiments, a few things were noted, like color change and 
precipitate being formed in solution.  For example, both of the solutions that were at a 
final pH of 7, were both translucent, but had a color of yellow.  But with both solutions 
that had final pH’s of 3 were both translucent, colorless.  2 days later a color change in 
solution were seen, both solutions that were initially yellow went colorless and formed a 
moderate amount of black precipitate.  Both solutions that were initially colorless, had 
changed to a pale yellow color and also had black precipitate in solution that had formed 
2 days later.   
 NMR data together was put together to obtain some information to help determine 
what is being formed in solution.  Both concentrations of solutions at a pH of 3 showed 
on NMR data that the ‘en’ ligand dissociated from the platinum complex; while at a pH 
of 7, it did not.  This can be concluded that the ‘en’ ligand is capable of coming off, but 
only at a low pH.  There were also other peaks noted in the NMR spectra that were 
relatively similar to one another, but also one of the pH solutions would have a peak 
somewhere that the other did not.  For example, at a pH of 7, peaks at 2.8 ppm and 2.2 
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ppm are seen, but it’s not seen in the pH 3 solution NMR spectrum.  But at both pH’s 
there are peaks at 2.5 and 2.6 ppm.  At the time of writing this thesis, we have not come 
up with any conclusions for what these peaks are.  We have tried other experiments to try 
to see if we can figure it out, we have also done liquid/chromatography mass 
spectrometry, but have also not come up with any solid answers yet.   
 This experiment was completed using one solution at a pH of 3 and the other at 7, 
both solutions was also mixed as one platinum molecule for every one selenium 
molecule.  Here, the pH 3 solution shows the ‘en’ ligand comes off again, but does not at 
pH 7.  Inconclusive results were obtained for this experiment as well.  We have not 
completed any mass spectrometry at the time of the thesis being written.   
 It is important however, that with the latter of the experiments we make a note 
that the ‘en’ ligand only comes off here with a low pH of around 3, rather than at a higher 
pH of around 7.  For prior experiments in this thesis, we have finally captured the isomers 
being formed of the chelates for SeMet and Me4en, and the monoadducts that formed.  
Prior to this experiment it was noted that the monoadducts were formed so fast, it had not 
been captured, and there was no information on the stereochemistry formed from these 
reactants as well.  Now that we have made a few conclusions with a few bulky platinum 
compounds and these two selenium containing amino acids, we will continue to further 
explore other bulky platinum compounds with the amino acids.  We will also further 
investigate our SeCys and Pt(en) compounds and get some finite results and answers and 
publish them.   
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 Platinum compounds have been used alone and also in conjunction with other 
anti-cancer agents to fight the battle of cancer.  Since platinum has a high affinity for 
sulfur containing amino acids and proteins, it also has an even higher affinity for 
selenium containing amino acids and proteins.  These results produced in this research 
have contributed to the cancer research being conducted, it also gives insight into further 
research areas to explore. 
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